» Articles » PMID: 16095904

Do the Histologic Features and Results of Breast Cancer Biomarker Studies Differ Between Core Biopsy and Surgical Excision Specimens?

Overview
Journal Breast
Publisher Elsevier
Specialties Endocrinology
Oncology
Date 2005 Aug 13
PMID 16095904
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Core biopsies are commonly used in the diagnosis of breast cancer and often are the only sample for providing prognostic and predictive markers prior to neoadjuvant chemotherapy. We retrospectively studied 87 patients with breast cancer to compare the concordance rates for tumor type, grade, estrogen receptor/progesterone receptor (ER/PR), p53 status and Her2/neu by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) between core and excisional biopsy specimens. The histologic type of cancer had a 100% concordance rate between core and excisional biopsy specimens. The concordance rate of modified Bloom-Richardson score between core and excisional biopsy specimens was 77%, ER was 95%, PR was 89%, and p53 was 86%. The concordance rate for Her2/neu by IHC was 96% and that for FISH was 100% between the core and excisional biopsy specimens. Although breast cancer may have heterogeneous histological and immunohistochemical findings, our study shows that relatively high concordance rates can be obtained when comparing core and excisional biopsy specimens.

Citing Articles

Preoperatively predicting human epidermal growth factor receptor 2-low expression in breast cancer using neural network model based on multiparameter magnetic resonance imaging.

Zhao S, Chen P, Wang X, Zheng Z, Hui R, Pang G Quant Imaging Med Surg. 2024; 14(12):8387-8401.

PMID: 39698610 PMC: 11652052. DOI: 10.21037/qims-24-428.


Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status.

Na S, Kim M, Park Y, Kwon H, Shin H, Kim E Breast Cancer. 2024; 31(4):705-716.

PMID: 38643429 PMC: 11194196. DOI: 10.1007/s12282-024-01585-3.


Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment.

Anderle N, Schafer-Ruoff F, Staebler A, Kersten N, Koch A, Onder C J Exp Clin Cancer Res. 2023; 42(1):210.

PMID: 37596623 PMC: 10436441. DOI: 10.1186/s13046-023-02782-2.


Identification of triple-negative breast cancer and androgen receptor expression based on histogram and texture analysis of dynamic contrast-enhanced MRI.

Xu W, Zheng B, Lu J, Liu S, Li H BMC Med Imaging. 2023; 23(1):70.

PMID: 37264313 PMC: 10236691. DOI: 10.1186/s12880-023-01022-5.


Concordance of immunohistochemistry for predictive and prognostic factors in breast cancer between biopsy and surgical excision: a single-centre experience and review of the literature.

Rossi C, Fraticelli S, Fanizza M, Ferrari A, Ferraris E, Messina A Breast Cancer Res Treat. 2023; 198(3):573-582.

PMID: 36802316 PMC: 10036406. DOI: 10.1007/s10549-023-06872-9.